Topic: Market Analysis

  • The Drugs at the Heart of Our Pricing Crisis

  • Biosimilars: Market Changes do not equal policy success

  • Modeling P-quad

  • Time to Throw in the Towel on Biosimilars

  • Understanding the Rewards of Successful Drug Development: Thinking Inside the Box

  • Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries

  • Abandon Biosimilars as Biologics are Natural Monopolies

  • DPL responds to HHS Blueprint (May 16, 2018)

  • R&D Costs Do Not Explain Elevated U.S. Drug Prices

  • Pricing in the Market for Anticancer Drugs